Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
- 15 July 2011
- journal article
- research article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 187 (2), 676-683
- https://doi.org/10.4049/jimmunol.1003884
Abstract
Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 59AMP in a CD73-dependent manner. However, 59AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment. The Journal of Immunology, 2011, 187: 676-683.This publication has 45 references indexed in Scilit:
- Proteomics Analysis of Bladder Cancer ExosomesMolecular & Cellular Proteomics, 2010
- CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune SuppressionCancer Research, 2010
- Generation and Accumulation of Immunosuppressive Adenosine by Human CD4+CD25highFOXP3+ Regulatory T CellsOnline Journal of Public Health Informatics, 2010
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasisProceedings of the National Academy of Sciences of the United States of America, 2010
- Membrane vesicles as conveyors of immune responsesNature Reviews Immunology, 2009
- Adenosine receptors: therapeutic aspects for inflammatory and immune diseasesNature Reviews Drug Discovery, 2008
- Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppressionThe Journal of Experimental Medicine, 2007
- Adenosine receptor activation ameliorates type 1 diabetesThe FASEB Journal, 2007
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences of the United States of America, 2006
- Tumour-derived exosomes and their role in cancer-associated T-cell signalling defectsBritish Journal of Cancer, 2005